Table 2.
Median HDR dose delivered to prostate and organs at risk
| Prescribed treatment dose (Gy) | All patients | With HS (n = 32) | Without HS (n = 65) | p-value |
|---|---|---|---|---|
| Median prostate volume (cc) | 44.6 (23.3-117.5) | 46.7 (30.3-84.5) | 43.1 (23.3-117.5) | 0.95 |
| Prostate | ||||
| V100 | 95.4 (84.3-98.9) | 94.9 (84.3-97.4) | 95.6 (88.1-98.9) | 0.05 |
| V150 | 32.4 (24.9-41.1) | 30.5 (24.9-34.8) | 33.5 (27-41.1) | 0.03 |
| V200 | 12.1 (9.6-15.7) | 11.7 (10.4-14.3) | 12.2 (9.6-15.7) | 0.06 |
| Rectal | ||||
| V75 (cc) | 0.32 (0-1.46) | 0 (0-0.22) | 0.45 (0-1.46) | < 0.001 |
| Urethral | ||||
| V125 (cc) | 0.04 (0-1.01) | 0.02 (0-0.66) | 0.06 (0-1.46) | 0.02 |
| Penile bulb | ||||
| 0.1 cc | 0.78 (0.45-1.69) | 0.83 (0.45-1.43) | 0.76 (0.46-1.69) | 0.30 |
| 1 cc | 7.84 (4.48-16.95) | 8.38 (4.48-14.29) | 7.59 (4.64-16.95) | 0.30 |
| 2 cc | 15.69 (8.97-33.89) | 16.65 (8.97-28.58) | 15.18 (9.28-33.89) | 0.31 |
| Bladder | ||||
| V70 (cc) | 4.22 (0.03-13.3) | 3.58 (0.3-10.97) | 4.37 (0.55-13.3) | 0.26 |
| V80 (cc) | 2.60 (0.00-9.5) | 2.30 (0.00-7.6) | 2.86 (0.14-9.5) | 0.25 |
HS – hydrogel spacer